Oxigene Inc. (NASDAQ:OXGN) said on Tuesday that its experimental drug Zybrestat combined with Roche’s big selling cancer drug Avastin significantly slowed progression of recurrent ovarian cancer better than Avastin alone in a midstage clinical trial. OXiGENE Inc. (NASDAQ:OXGN) stock opened at $2.10 in last session, and closed at $2.42, while the day range of OXiGENE Inc. (NASDAQ:OXGN) stock is $2.09 – $2.45. The stock showed a positive weekly performance of 15.79%.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA) on Mar. 11 reported financial results for the fourth quarter and year ended December 31, 2013 and provided an update on recent corporate events. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) stock opened at $5.30 in last session, and closed at $5.28 by gaining 4.35%. The 52 week range of $3.70 – $10.74. Company’s market capitalization is $364.57 million.
Goldman Sachs upgraded InterMune Inc. (NASDAQ:ITMN) from Neutral to Buy with a price target of $45.00 (from $40.00), suggesting 34% upside. InterMune Inc. (NASDAQ:ITMN) stock decreased -1.37% and finished the last session at $33.18. The EPS of the stock remained -2.71. Company’s market capitalization is $2.84 billion.
Progenics Pharmaceuticals, Inc., (NASDAQ:PGNX) , an oncology company focused on developing innovative ways to target and treat prostate cancer, announced that it will host a conference call and webcast to review fourth quarter and full-year 2013 financial results on Thursday, March 13, at 8:30 a.m. ET. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) stock opened the session at $4.61, and closed the session at $4.71. The 52 week range of the Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) stock remained $3.13 – $7.45 and the day range was $4.51 – $5.04.